Altogether, these results in Figure 3 suggest that increased IL-1 signaling may be involved in erlotinib resistance and this increased IL-1 signaling in ER-HNSCC cells may be due to reduced IL-1RA protein secretion. This evidence concerns the gene IL1RN and head and neck squamous cell carcinoma.